Journal of Nanotheranostics

Pulmonary diseases, including tuberculosis (TB), chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis, remain a leading cause of morbidity and mortality worldwide, and each presents a different combination of diagnostic and therapeutic problems. Theranostic nanoparticles, which carry diagnostic and therapeutic functions in a single construct, have been proposed as a way to address both at once. Inorganic nanoparticles are attractive for this purpose because their optical, magnetic, and structural properties are tunable and because their surfaces tolerate extensive modification. The term theranostic, however, is applied inconsistently: much of the literature described as theranostic reports particles characterized for imaging or for therapy, but not for both on the same construct. This review applies an explicit three-tier definition, distinguishing shared-mechanism platforms, integrated platforms whose diagnostic and therapeutic modes act independently, and single-function platforms with theranostic potential. We use it to assess gold nanoparticles (GNPs), silver nanoparticles (AgNPs), mesoporous silica nanoparticles (MSNs), superparamagnetic iron oxide nanoparticles (SPIONs), and quantum dots (QDs) in pulmonary disease. Attention is given to lung-specific constraints: the difference between inhaled and systemic administration, aerodynamic requirements for deposition, mucus and surfactant interactions, alveolar macrophage uptake, mucociliary clearance, and barriers that differ between fibrotic, infective, inflammatory, and malignant disease. We address limitations by material class rather than generically, because the dominant risk differs among silver ion release, gold persistence, iron-mediated redox chemistry, silica dissolution, and heavy metal leaching from QD cores. Several inorganic nanoparticle formulations have regulatory approval, but pulmonary theranostic applications remain preclinical, and we outline what would be required to change that. Full article

Immunotherapy can reduce treatment-related side effects but shows limited efficacy in “cold tumors,” whose immunosuppressive tumor immune microenvironment is characterized by abundant M2 macrophages and poor T cell infiltration. Because biopsy-based qualitative assessment of the tumor microenvironment is invasive and conventional imaging lacks functional information, this study aimed to develop an M2 macrophage-targeted theranostic agent enabling non-invasive photoacoustic (PA) imaging and pH-triggered cytotoxicity. A pullulan-based nanogel conjugated with mannose and near-infrared dye (IR-820) was further functionalized with the pH-responsive doxorubicin (DOX) prodrug, Aldoxorubicin, to develop Pullulan-mannose-IR820-Aldoxorubicin (PMID) nanogel. PMID was successfully synthesized, and the resulting self-assembled nanogels (<100 nm) exhibited a highly negative ζ-potential, near-infrared absorption peaks at 780 and 850 nm, and PA contrast comparable to IR-820 at 850 nm excitation. Dialysis studies demonstrated suppressed drug release at neutral pH (~20%) but accelerated release under acidic conditions, reaching ~80% within 48 h at pH 5.5, consistent with hydrazone hydrolysis and supporting tumor/lysosome-activated delivery. In RAW264.7 macrophages, PMID nanogel showed preferential uptake by M2-poralized versus M1-polarized macrophages, outperforming non-mannosylated PID nanogel and IR-820, and produced the strongest PA signal in M2 macrophage pellets. PMID nanogel also induced the highest concentration-dependent cytotoxicity in M2 macrophages, and microscopy indicated lysosomal accumulation of the nanogel with partial nuclear localization of released DOX. These findings support the use of PMID nanogel as M2 macrophage-targeted PA contrast agents and pH-responsive drug carriers with the potential to deplete immunosuppressive macrophages, modulate cold tumor microenvironments, and improve precision cancer theranostics. Full article

Hydrogel-forming microneedles (HFMNs) are minimally invasive interfaces that access interstitial fluid (ISF) through skin penetration, swelling-mediated uptake, analyte diffusion, and hydrated sensor integration. This review examines HFMN architectures, skin–device interfaces, ISF transport, molecular-recognition and signal-transduction strategies, analytical performance, benchmarking, wear-associated failure modes, therapeutic monitoring, and translational priorities. The field has expanded from glucose sensing to metabolites, ions, hormones, proteins, nucleic acids, microbial and wound biomarkers, and therapeutic drugs, enabled by advances in hydrogel chemistry, conductive networks, nanostructured electrodes, catalysis, affinity recognition, molecular imprinting, optical readouts, and multiplexed wearables. Performance remains context dependent and requires physiological range, calibration stability, biofouling resistance, reliable insertion, validated ISF-reference correlations, and interpretable thresholds. Evidence is strongest in artificial matrices, ex vivo tissue, and animals, while human validation remains limited. Translation will require standardized mechanics and transport reporting, longer wear studies, sterilization-compatible chemistries, scalable manufacturing, and clinical validation. HFMNs may complement rather than replace blood-based diagnostics. Full article

Theranostic nanoparticles, which integrate diagnostic imaging and therapeutic delivery within a single nanoplatform, represent a transformative paradigm in oncological nanomedicine. Despite substantial preclinical progress, the field faces persistent gaps in rational nanoparticle design informed by tumor biology, preclinical model fidelity, and clinical translation. This review critically synthesizes theranostic nanoparticle research across three underexplored domains. First, we examine tumor microenvironment features—reactive oxygen species dynamics, glutathione gradients, hypoxia, and proteasomal dysregulation—as mechanistic drivers of nanoparticle responsiveness. Second, we evaluate redox-responsive and proteasome-targeted nanoplatforms that exploit these cues for stimuli-triggered drug release and simultaneous imaging readout. Third, we address the unmet need for three-dimensional organoid and microfluidic tumor models as predictive preclinical testing environments, given the well-documented limitations of conventional two-dimensional cultures. Cancer subtype-specific applications are discussed for breast cancer, HPV-associated malignancies, colorectal cancer, and prostate cancer. Clinical translation barriers—including pharmacokinetic constraints, protein corona formation, immune clearance, anti-PEG antibodies, complement activation-related pseudoallergy, and FDA/EMA regulatory pathways—are addressed from a clinical oncology perspective. The review concludes with a research roadmap integrating proteomics-guided nanoparticle engineering, patient-derived organoid biobanks, and artificial intelligence-assisted design as priority areas for next-generation oncological theranostics. Full article

Cancer diagnosis and longitudinal monitoring increasingly depend on biosensing technologies capable of detecting low-abundance, heterogeneous, and dynamic biomarkers in complex biological samples. Hydrogel-based biosensors offer a distinctive materials platform for this purpose because their hydrated, porous, tunable, and biomolecule-compatible networks can integrate molecular recognition, antifouling protection, nanomaterial-assisted signal amplification, and three-dimensional biological interfaces within a single sensing architecture. Across cancer-focused applications, hydrogels have been engineered to detect nucleic acids, soluble protein markers, tumor-associated enzymes, extracellular vesicles, circulating tumor cells, metabolic products, redox signals, and tumor microenvironmental cues in matrices such as serum, plasma, saliva, urine, sweat, blood, cell lysates, and three-dimensional cancer models. Their functional value extends beyond passive immobilization: hydrogels can serve as programmable recognition networks, gated reservoirs, conductive interfaces, optical and plasmonic scaffolds, degradable enzyme-responsive matrices, and cell-compatible microenvironments. These attributes support sensitive biomarker detection, multiplexed profiling, portable and smartphone-assisted formats, wearable or minimally invasive systems, and dynamic monitoring of tumor behavior and treatment response. Nevertheless, the field remains uneven in translational maturity, with many platforms still requiring broader clinical validation, standardized benchmarking, manufacturable device designs, reproducible fabrication, and practical assessment of assay complexity, storage stability, and patient-sample performance. This review positions biomarker-responsive hydrogels as a convergence point between advanced materials engineering and clinically oriented cancer biosensing, with particular promise for liquid biopsy, decentralized diagnostics, and tumor-state-resolved monitoring. Full article

Asthma is a prevalent, long-term inflammatory airway condition that is difficult to diagnose and treat because there is no single reliable diagnostic test. Misdiagnosis is therefore common, with rates as high as 73% in juvenile groups and up to 35% in adult populations. This ultimately exacerbates their illness by postponing therapy for some people and administering needless medication to others. Although well-known biomarkers such as blood eosinophils and fractional exhaled nitric oxide, as well as conventional diagnostic techniques such as spirometry, have improved clinical assessment, they are nevertheless constrained in many healthcare settings by limited availability, high cost, and inconsistent use. Furthermore, these indicators primarily reflect type-2 inflammation and are less useful for non-type-2 asthma, highlighting the need for more comprehensive, readily accessible diagnostic techniques. Identifying novel biomarkers of oxidative stress, metabolic alterations, and airway inflammation, including volatile organic compounds and redox-related chemicals, has been the focus of recent studies. These biomarkers offer opportunities for improved disease phenotyping and non-invasive detection. Simultaneously, advances in biosensor technology have enabled highly sensitive platforms to rapidly detect these biomarkers at low concentrations. In particular, optical biosensors are becoming more and more popular due to their ability to do real-time detection without the need for labels and their ease of miniaturization for point-of-care devices. This work summarizes traditional diagnostic tools alongside existing information on asthma phenotypes and clinically important biomarkers, and discusses advanced biosensors ranging from electrochemical to optical systems, including recent developments in nanomaterial-enhanced optical biosensing techniques. The importance of artificial intelligence and smartphone-integrated hardware is also covered, along with the main challenges that need to be overcome for these technologies to become useful clinical tools for asthma diagnosis and monitoring. Full article

Theranostics is a novel approach that integrates diagnostic and therapeutic efficacy on a single platform, holding great promise for precision medicine by enabling real-time monitoring of disease progression and therapeutic response. Despite significant advances, the successful development and delivery of theranostic systems are critically limited by multiple biological barriers present at systemic, tissue, cellular, anatomical, and immunological levels. These barriers restrict bioavailability, target accessibility, and therapeutic efficacy, while often increasing off-target accumulation and adverse effects. This review provides a comprehensive overview of the major biological barriers encountered in theranostic development, including physiological barriers such as plasma protein binding, renal clearance, and hepatic metabolism; anatomical barriers like endothelial linings, the blood–brain barrier (BBB), and the tumor microenvironment; cellular barriers involving membrane permeability, intracellular trafficking, and endo-lysosomal entrapment; and immunological barriers such as immune recognition, inflammatory responses, and complement activation. Special emphasis is placed on the BBB, highlighting its structural complexity, transport mechanisms, and strategies such as molecular Trojan-horse technology, receptor-mediated and adsorptive-mediated transcytosis, and nanocarrier-based approaches to enhance central nervous system delivery. The review further discusses targeted delivery challenges, including receptor heterogeneity and multidrug resistance, and critically evaluates current strategies to overcome these barriers through surface functionalization, stimuli-responsive systems, biomimetic carriers, and controlled-release mechanisms. Finally, recent advances, clinical challenges, and future perspectives—including personalized theranostics, artificial intelligence—assisted design, and next-generation barrier-penetrating systems—are explored. Overall, this review aims to provide a structured understanding of biological barriers in theranostics and highlight innovative approaches to improve their translational potential. Full article

DNA methylation is a key mechanism in epigenetic regulation and plays a pivotal role in tumor initiation, progression, and therapeutic resistance. We begin by elucidating how the dysregulation of key DNA methylation enzymes in tumors drives concurrent global hypomethylation and cytosine-phosphate-guanine (CpG) island hypermethylation. This aberrant epigenetic landscape promotes tumorigenesis through silencing tumor suppressor genes and triggering abnormal activation of oncogenic signaling pathways. Notably, DNA methylation is intimately linked to cellular pyroptosis. In particular, the hypermethylation-mediated silencing of pyroptosis effector genes represents a critical epigenetic mechanism underlying acquired drug resistance. Targeting DNA methylation with epigenetic drugs offers a novel strategy to resensitize tumors to chemotherapy, radiotherapy, and immunotherapy. Moreover, advances in nanomedicine have yielded smart platforms for the precise administration of epigenetic modulators and combination therapies. These platforms enable a coordinated “epigenetic priming-pyroptosis execution” strategy, which holds promises for reversing therapeutic resistance and remodeling the tumor immune microenvironment. By integrating DNA methylation regulation, pyroptosis mechanisms, and nano-targeted strategies, this review aims to provide a theoretical framework and novel perspectives for developing innovative, epigenetically driven anti-tumor therapies. Full article

Nanomaterial-based biosensors have advanced analytical methodologies by enhancing signal transduction, interfacial reactivity, and molecular recognition across diverse sensing platforms. In parallel, the diversity of nanomaterial compositions, architectures, and interfacial designs has expanded the range of available sensing strategies and performance outcomes. This review addresses limitations through a structure–property–function framework that links nanomaterial characteristics to sensing behavior, performance determinants, and application-specific requirements. Within this framework, nanomaterials are classified according to their dominant functional roles in biosensing, including plasmonic, electroactive, fluorescent and quantum-confined, porous, and hybrid architectures. The influence of morphology, surface chemistry, conductivity, and interfacial design on electrochemical, optical, and hybrid transduction mechanisms is critically examined, and key performance parameters, including sensitivity, selectivity, limit of detection, response time, stability, and reproducibility, are discussed in relation to material properties and sensing configuration. Recent advances in clinical biomarker detection, pathogen and nucleic acid analysis, and environmental and food safety monitoring are also evaluated to illustrate how nanomaterial design is tailored to different analytical contexts. Current limitations related to reproducibility, interface engineering, long-term stability, and scalable device integration are highlighted, together with future directions for the rational development of robust and application-oriented biosensor platforms. Full article

Nanoparticles offer a versatile platform for the selective eradication of pathogenic or diseased cells by integrating therapeutic payload delivery with precision targeting. Precision targeting can be achieved (1) actively through ligand conjugation, (2) passively by exploiting the physiological abnormalities of diseased tissues, or (3) intrinsically through the innate biophysical properties of the nanoparticle. Intrinsically selective nanoplatforms (iNPs) are particularly advantageous when the disease-promoting agent does not possess distinct surface markers, such as in the case of certain “untargetable cancers” or cancers without known targets. Indeed, nanocarriers for chemotherapeutic or gene delivery have achieved selective cancer cell apoptosis without requiring marker presentation, thereby expanding the therapeutic window of the payload. Disease-promoting agents whose physical properties are different from those of healthy cells are also good candidates for intrinsic nanoparticle targeting. For example, antimicrobial nanomaterials have been designed to disrupt bacterial membranes and reduce the risk of antimicrobial resistance by leveraging stiffness differentials between bacterial cell walls and eukaryotic membranes. Nanoparticle systems with intrinsic targeting mechanisms can also enable non-invasive imaging with near-infrared fluorescence, MRI, and photoacoustic imaging for real-time biodistribution tracking and treatment monitoring. This review synthesizes current innovations in nanoplatform design with intrinsic targeting capabilities, spans applications in infectious and non-communicable diseases, and discusses emerging strategies to enhance specificity, overcome resistance, and translate these platforms toward clinical and field deployment. Full article

Background: Conventional therapeutic and diagnostic approaches, despite improving clinical outcomes, remain limited by poor bioavailability, inadequate targeting, suboptimal pharmacokinetics, and systemic toxicity, particularly in complex diseases. To overcome this, nanomedicine has emerged as a transformative strategy, employing engineered nanoparticles to enhance drug stability, controlled release, targeted delivery, and diagnostic performance, thereby enabling theranostic applications. This review evaluates major nanoparticle platforms in therapy and diagnosis, comparing their mechanisms, applications, and challenges while highlighting their potential to advance precision medicine and theranostic strategies. Method: For providing the context and evidence, relevant literatures were sourced from Google Scholar, PubMed, and ScienceDirect using targeted keywords including “drug delivery,” “diagnostics,” “nanoparticles,” “nanomedicine,” “nano drug delivery,” “nanotheranostics,” “targeted therapy,” “controlled drug release,” “solid lipid nanoparticles (SLNs),” “lipid nano carriers (LNCs),” and “inorganic nanoparticles.” Although no strict time limit was applied during the literature search, clinical trial data were collected and analyzed up to January 2026. Given that clinical trial registries are continuously updated, the included trials represent the status at the time of data retrieval. However, it is pertinent to note that the earliest relevant studies appeared in 1973. Conclusions: This review highlights nanoparticle fundamentals, major material classes, mechanisms of action, and applications in targeted therapy, imaging, and theranostics. It also addresses translational barriers related to safety, scalability, biological complexity, and regulatory compliance. Overcoming these challenges through standardized characterization and interdisciplinary collaboration is crucial for clinical adoption. Future efforts should focus on AI-driven design, computational tools, smart nanomedicines, and advanced biosensing technologies to integrate nanoparticle-enabled precision diagnostics and therapy into routine clinical practice. Full article

Nanotheranostic platforms integrating diagnostic and therapeutic functions within a single system have attracted significant attention in precision medicine. However, conventional nanotheranostics based on systemic administration often suffer from off-target accumulation, limited retention at disease sites, and dose-limiting toxicity. To address these limitations, hydrogel-integrated nanotheranostic systems have emerged as a promising strategy for achieving localized diagnosis and therapy with improved spatial control and safety. This review provides a comprehensive overview of recent advances in hydrogel–nanomaterial nanotheranostic platforms, focusing on their design principles, diagnostic capabilities, and therapeutic applications. We discuss the complementary roles of hydrogels and nanomaterials, where hydrogels function as localized reservoirs and tissue interfaces, and nanomaterials provide imaging and therapeutic functionalities. Key integration strategies including physical encapsulation, chemical conjugation, and in situ nanoparticle formation are systematically compared. We further summarize localized diagnostic modalities such as real-time imaging and therapy monitoring, and highlight research-driven applications in cancer treatment, inflammation and infection management, and tissue regeneration. Finally, major translational challenges and future perspectives toward personalized, image-guided local theranostics are discussed. Overall, hydrogel-based nanotheranostic platforms represent a versatile approach for next-generation localized precision medicine. Full article

Personalized medicine aims to tailor therapy based on patient-specific molecular and biological characteristics, while nanomedicine focuses on engineering delivery systems to overcome pharmacokinetic and biological barriers. Despite major advances, both fields are limited when applied separately. This review discusses integrating patient stratification with rational nanocarrier design, a combination termed personalized nanomedicine, as a framework to maximize therapeutic index. With emphasis on clinically validated and late-stage examples, we analyze how molecular stratification informs therapeutic design, with particular focus on translational constraints and engineering trade-offs. Results: Personalized medicine enables precise target identification and patient stratification but does not address delivery barriers that limit therapeutic distribution and safety. Conversely, nanomedicine overcomes delivery challenges but exhibits patient- and disease-dependent variability. Merging these approaches allows nanocarrier design to be tailored to disease biology and patient-specific barriers to effective treatment. Recent clinically successful examples demonstrate that co-optimizing biological targeting and delivery engineering can improve translational robustness. Conclusions: Personalized nanomedicine represents a convergence of molecular stratification and engineered delivery systems, a fusion that facilitates context-dependent therapeutic design rather than one-size-fits-all formulations. While significant translational and regulatory challenges remain, treating delivery design as an integral component of personalization offers a viable path toward broader clinical implementation. Continuing to integrate patient profiling with nanoengineering principles will be essential for translating personalized nanomedicine from promising case studies into standard clinical practice. Full article

Glioblastoma (GBM) remains among the most treatment-refractory human malignancies. It is characterized by profound radioresistance and a highly immunosuppressive tumor microenvironment, limiting the durable efficacy of radiotherapy. Beyond direct cytotoxicity, ionizing radiation can induce immunogenic cell death and the release of damage-associated molecular patterns (DAMPs), including surface-exposed calreticulin, HMGB1, extracellular ATP/adenosine, and tumor-derived DNA. These signals engage pattern-recognition receptors and cGAS–STING–type I interferon pathways, transiently promoting antigen presentation and immune activation. In GBM, however, DAMP signaling frequently evolves toward chronic inflammation and immune suppression, characterized by myeloid cell recruitment, adenosine accumulation, and immune checkpoint upregulation, thereby contributing to tumor regrowth and radioresistance. This dual immune-regulatory role of DAMPs highlights the importance of temporal and contextual interpretation of radiation-induced immune responses. In this review, we summarize current mechanistic and translational evidence on DAMP-mediated immunomodulation in GBM radiotherapy; discuss modality-dependent considerations across photon, proton, and high-LET irradiation; and evaluate the emerging potential of DAMPs as dynamic biomarkers of treatment response. We further outline how integration of DAMP profiling with liquid biopsy, imaging, and nanotheranostic platforms may support biologically informed and adaptive radiotherapy strategies for glioblastoma. Full article

The usage of magnetic nanoparticles (MNPs), particularly iron oxide-based systems such as magnetite (${\mathrm{Fe}}_3$${\mathrm{O}}_4$) and maghemite ($\gamma$-${\mathrm{Fe}}_2$${\mathrm{O}}_3$), has significantly advanced the field of theranostics. These nanoparticles unite therapeutic and diagnostic capabilities due to their favorable magnetic properties and surface engineering potential. However, the path from synthesis to clinical application poses substantial challenges, including optimization of structure–property–function relationships, biocompatibility issues, and effective surface functionalization. Various synthesis methods, such as co-precipitation and thermal decomposition, aim to achieve specific nanoparticle characteristics, although they encounter obstacles related to scalability and reproducibility. Furthermore, characterizing these systems through structural, microstructural and spectroscopic techniques is vital to determine their functional efficacy and ensure their safe biomedical usage. This review comprehensively examines recent advancements and identifies existing challenges in the clinical translation of MNPs, highlighting the need for refined methods and standardized protocols to effectively exploit their theranostic potential. It outlines future directions, emphasizing the importance of green synthesis and robust characterization frameworks to enhance the integration of MNPs in personalized medicine. Full article

While CRISPR-Cas9 enables precise targeting of cancer-driving genetic aberrations, its clinical application is impeded by instability, delivery inefficiencies, and immunogenicity. Nanotechnology addresses these challenges by engineering nanocarriers that facilitate enhanced cellular uptake, promote efficient endosomal escape, and ensure targeted delivery. This review summarizes current progress in nano-integrated CRISPR-Cas systems for cancer therapeutics, highlighting recent advancements in stimuli-responsive nanoplatforms for precise genome editing and their prospects for clinical application. Full article

Acute and chronic kidney diseases remain significant challenges in regenerative medicine, with few therapies capable of reversing tissue injury or preventing progression. Bone marrow mesenchymal stem cell-derived exosomes (BM-MSC-Exos) are nanosized vesicles (30–150 nm) that have emerged as multifunctional nanotheranostic platforms, combining targeted therapeutic activity with imaging-enabled monitoring. In renal pathophysiology, BM-MSC-Exos exert anti-inflammatory, anti-fibrotic, angiogenic, and pro-regenerative effects. These actions are mediated by microRNAs, messenger RNAs, mitochondrial regulators, and bioactive proteins that modulate epithelial repair and immune responses. Recent bioengineering advances enable more precise BM-MSC-Exos design, including enrichment with synthetic RNAs or gene-editing components and membrane functionalization to enhance kidney tropism. In parallel, fluorescence, bioluminescence, and nanoparticle-based approaches support in vivo tracking. These tools allow real-time assessment of biodistribution and tubular uptake, strengthening evidence for target engagement. This review synthesizes current knowledge on BM-MSC-Exos in renal repair. We summarize contemporary strategies for cargo and surface engineering, outline imaging methodologies for in vivo tracking, and discuss how administration routes influence renal targeting. We also provide an updated overview of clinical trials evaluating exosomes as therapeutic agents or biomarkers in nephrology. Collectively, engineered BM-MSC-Exos represent a promising and increasingly sophisticated platform for precision-guided kidney therapy, supported by monitoring tools that facilitate preclinical evaluation of biodistribution and efficacy. Full article

Metal–organic frameworks (MOFs) are among the most structurally diverse classes of crystalline nanomaterials, offering exceptional tunability, porosity, and chemical modularity. These characteristics have positioned MOFs as promising platforms for nanomedicine, bioimaging, and integrated nanotheranostic applications. However, the rational design of MOFs that satisfy stringent biomedical requirements, including high drug loading capacity, controlled and stimuli responsive release, selective targeting, physiological stability, biodegradability, and multimodal imaging capability, remains challenging due to the vast combinatorial design space and the complex interplay between physicochemical properties and biological responses. The objective of this review is to critically examine recent advances in artificial intelligence approaches based on Transformer architectures for the design and optimization of MOFs aimed at next-generation nanotheranostics. In contrast to prior reviews that broadly survey machine learning methods for MOF research, this article focuses specifically on Transformer-based models and their ability to capture long-range, hierarchical, and multiscale relationships governing MOF structure, chemistry, and functional behavior. We review state-of-the-art models, including MOFormer, MOFNet, MOFTransformer, and Uni MOF, and discuss graph-based and sequence-based representations used to encode MOF topology and composition. This review highlights how Transformer-based models enable predictive assessment of properties directly relevant to nanotheranostic performance, such as adsorption energetics, framework stability, diffusion pathways, pore accessibility, and surface functionality. By explicitly linking these predictive capabilities to drug delivery efficiency, imaging performance, targeted therapeutic action, and combined diagnostic and therapeutic applications, this work delineates the specific contribution of Transformer-based artificial intelligence to biomedical translation. Finally, we discuss emerging opportunities and remaining challenges, including generative Transformer models for inverse MOF design, self-supervised learning on hybrid experimental and computational datasets, and integration with autonomous synthesis and screening workflows. By defining the scope, novelty, and contribution of Transformer-based design strategies, this review provides a focused roadmap for accelerating the development of MOF-based platforms for next-generation nanotheranostics. Full article